Insider transaction
Christine Ring, Nurix Therapeutics' chief legal officer, sold 8,148 shares of the companys common stock on April 2, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares traded at prices between $15.00 and $15.43, producing a weighted average price of $15.2367 and a total transaction value of $124,148.
The filing shows that, after the sale, Ring directly holds 26,453 shares of Nurix Therapeutics. The disposition was carried out under a pre-arranged Rule 10b5-1 trading plan, the filing indicates.
Market context and valuation signal
Nurix shares have risen roughly 71% over the past six months. Despite that run, InvestingPro data cited in the filing suggests the stock remains slightly undervalued at current prices. The filing lists the transaction details and reiterates the availability of further company analysis and ProTips through InvestingPro for investors seeking a deeper view of Nurixs financial position and valuation metrics.
Capital markets activity
Separately, Nurix announced an amendment to its equity distribution agreement with Piper Sandler & Co., expanding its capacity to offer and sell up to $413.65 million of its common stock through "at the market" offerings. Under the amended arrangement, Piper Sandler will act as sales agent for the shares sold under the program. The amendment is positioned as part of the companys capital-raising strategy.
Recent financial results and analyst responses
Nurix reported fourth-quarter fiscal 2025 results that included a net loss of $0.82 per share. That result was marginally better than H.C. Wainwrights estimate of a $0.84 per share loss. Following the quarter, H.C. Wainwright raised its price target for Nurix to $32 and reiterated a Buy rating.
Stifel also lifted its price target to $35, citing the potential of Nurixs bexobrutideg program, which the company is advancing with two registrational trials. Piper Sandler increased its own price target to $35 while maintaining an Overweight rating, referencing Nurixs acceleration of development plans for bexobrutideg in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Clinical program and upcoming scientific presence
Nurix plans to present at the upcoming AACR Annual Meeting. The company is scheduled for two oral presentations and three poster presentations drawn from its research portfolio, indicating continued activity on the clinical and scientific fronts.
What this means
The filing documents an individual insider sale executed via a pre-arranged trading plan and updates investors on corporate financing flexibility and recent operating results. The companys amended ATM capacity provides a defined mechanism to raise capital, while the quarter results and subsequent analyst adjustments reflect market attention to both financial performance and the developmental trajectory of Nurixs lead program, bexobrutideg. Investors and market participants will have access to additional analytical materials through InvestingPro as noted in the filing for those seeking more detailed financial and valuation context.
Disclosure
No disclosure was provided in the companys Form 4 beyond the transaction details and statement of the trading plan under which the sale was executed.